RemeGen Issues Unaudited 2026 First-Quarter Report and Cautions Investors

RemeGen Co. Ltd. Class H ( (HK:9995) ) has provided an announcement.

RemeGen Co., Ltd. has released its unaudited 2026 first quarterly report, prepared under PRC accounting principles for compliance with STAR Market requirements, and clarified that these figures differ from those prepared under International Financial Reporting Standards. The board and senior management emphasize the truthfulness and completeness of the disclosed data, while warning shareholders and potential investors to exercise caution when trading the company’s securities given that the financial information has not been reviewed by independent auditors.

The announcement, issued under Hong Kong listing and securities laws, highlights the company’s dual‑market regulatory obligations and its effort to provide translated financial information to offshore investors. By formally affirming board responsibility and disclosing the review by the audit committee, RemeGen aims to maintain transparency and corporate governance standards, though the unaudited status of the figures may temper investor confidence in making fully informed decisions.

The most recent analyst rating on (HK:9995) stock is a Buy with a HK$129.00 price target. To see the full list of analyst forecasts on RemeGen Co. Ltd. Class H stock, see the HK:9995 Stock Forecast page.

More about RemeGen Co. Ltd. Class H

RemeGen Co., Ltd. is a joint stock company incorporated in the People’s Republic of China and listed in Hong Kong and on Shanghai’s STAR Market. The company operates in the biopharmaceutical sector, focusing on innovative therapies and leveraging China’s domestic capital markets for funding and growth.

Average Trading Volume: 4,130,217

Technical Sentiment Signal: Buy

Current Market Cap: HK$75.48B

For detailed information about 9995 stock, go to TipRanks’ Stock Analysis page.